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Despite the remarkable clinical response of mela-
noma harboring BRAF mutations to BRAF inhibitors
(BRAFi), most tumors become resistant. Here, we
identified the downregulation of the ubiquitin ligase
RNF125 in BRAFi-resistant melanomas and demon-
strated its role in intrinsic and adaptive resistance
to BRAFi in cultures as well as its association with
resistance in tumor specimens. Sox10/MITF expres-
sion correlated with and contributed to RNF125
transcription. Reduced RNF125 was associated
with elevated expression of receptor tyrosine kinases
(RTKs), including EGFR. Notably, RNF125 altered
RTK expression through JAK1, which we identified
as an RNF125 substrate. RNF125 bound to and
ubiquitinated JAK1, prompting its degradation and
suppressing RTK expression. Inhibition of JAK1
and EGFR signaling overcame BRAFi resistance in
melanoma with reduced RNF125 expression, as
shown in culture and in in vivo xenografts. Our find-
ings suggest that combination therapies targeting
both JAK1 and EGFR could be effective against
BRAFi-resistant tumors with de novo low RNF125
expression.
INTRODUCTION
A missense mutation (V600E) in the activation loop of serine-
threonine protein kinase B-RAF (BRAFV600E) is the most preva-
lent coding region mutation in melanoma and is seen in >50%
of melanoma tumors (Davies et al., 2002). Tumors harboring
constitutively active BRAFV600E exhibit highly active mitogen-1458 Cell Reports 11, 1458–1473, June 9, 2015 ª2015 The Authorsactivated protein kinase (MAPK) signaling, which is implicated
in their transformation (Lopez-Bergami, 2011).
Success in targeting oncogenic kinase activity has encouraged
the development of therapies targeting the BRAF mutation, an
approach that hasproducedagrowing numberofBRAF inhibitors
(BRAFi), including vemurafenib and dabrafenib. These reagents
represent significant advances in the clinicalmanagement ofmel-
anoma relative to the previous first-line therapy, dacarbazine
(Chapman et al., 2011; Flaherty et al., 2010; Hauschild et al.,
2012; Sosman et al., 2012). Nonetheless, some tumors treated
with BRAFi exhibit intrinsic drug resistance, while others develop
adaptive resistance over time. This remains a major obstacle in
the long-term effectiveness of BRAFi-based therapy (Ribas and
Flaherty, 2011) and thus is the subject of intense study.
Numerous pathways reportedly underlie BRAFi resistance,
including reactivation of MAPK signaling through NRAS or
MEK1mutations, BRAF splicing or gene amplification, and upre-
gulation of receptor tyrosine kinases (RTKs) or growth factors
(Abel et al., 2013; Nazarian et al., 2010; Poulikakos et al., 2011;
Shi et al., 2012; Wagle et al., 2011; Wilson et al., 2012). In addi-
tion, altered signaling pathways, such as PI3K/AKT/mTOR and
MITF/PGC1alpha, are implicated in BRAFi resistance (Haq
et al., 2013; Shi et al., 2011; Villanueva et al., 2010). However,
it is currently not possible to predict which tumors will exhibit
chemoresistance. These hurdles have stimulated interest in
novel combination therapies, including BRAFi, but it remains
challenging to identify which patients should undergo such reg-
imens (Sullivan and Flaherty, 2013). Defining the mechanisms
that underlie intrinsic/primary resistance or adaptive resistance
and detecting them prior to initiating treatment could accelerate
the development of rational combination therapies aimed at
overcoming BRAFi resistance.
Given the importance of ubiquitin proteasome system (UPS)
components in tumor development, progression, and resistance
mechanisms (Hoeller and Dikic, 2009; Qi et al., 2008, 2010,
2013), we sought to determine whether UPS components may
also contribute to BRAFi resistance of melanoma. To identify
components of the UPS that potentially drive BRAFi resis-
tance, we performed functional screening of a small interfering
RNA (siRNA) library against UPS-related genes. We then as-
sessed positive hits for differentially expressed genes in data
sets of BRAFi-resistant melanomas. The combined analyses
led us to identify the E3 ubiquitin ligase RNF125, which is
downregulated in resistant melanomas, as a component of
intrinsic resistance to BRAFi. We demonstrate the role of
RNF125 in regulating JAK1 and EGFR expression, and establish
the importance of this regulation for chemoresistance of mela-
noma to BRAFi.
RESULTS
Identification of RNF125 in BRAFi-Resistant Melanomas
To define mechanisms underlying melanoma cell resistance to
BRAFi, we evaluated the potential deregulation of UPS factors
in BRAFi-resistant melanoma. To this end, we performed an
unbiased screen of a siRNA library, including 1,173 genes en-
coding most of the UPS-associated proteins. We performed
the screen using melanoma cell lines (Lu1205 parental, sensitive
[Lu1205S]), which became resistant in the presence of in-
creasing concentrations (up to 5 mM) of the BRAFi PLX4032
(Lu1205 resistant [Lu1205R]; Figures 1A and S1A). As previously
reported, resistant cultures exhibited a high ERK activation
correlated with BRAFi resistance, with an overall IC50 increase
of 20- to 400-fold (Greger et al., 2012; Su et al., 2012; Figure S1A).
Potential changes in viability of the parental and BRAFi-resistant
Lu1205 cultures were monitored following transfection of cells
with three siRNAs targeting each of the 1,173 UPS-related genes
(Figure 1A). An initial screen of the parental line identified 18
genes for which inhibition conferred a growth advantage in the
presence of BRAFi (1 mM; Figures 1B and 1C). Among these
genes, inhibition of CUL3, RBX1, or WDR24 conferred the
most potent net growth advantage (Figures 1B and 1C). In agree-
ment with this finding, an independent study reported that
downregulation of Cul3 and Rbx1 confers a growth advantage
in melanoma cells treated with BRAFi (Shalem et al., 2014).
None of the UPS-related genes identified in the Lu1205S cells
were able to alter the growth of Lu1205R cells (Figure S1B).
Overall, we selected 18 genes for re-analysis in a second
BRAFi-resistant melanoma cell line (A375 resistant [A375R]),
again using three different siRNAs. Depletion of nine of the orig-
inal 18 genes significantly increased BRAFi resistance in both the
Lu1205 and A375 lines (Figure 1D).
To narrow the list of UPS-related candidate genes, we as-
sessed gene expression data sets obtained from melanoma
tumor-derived cultures resistant to BRAFi (GEO: GSE24862)
(Nazarian et al., 2010). Of 740 UPS-related genes, only 12
were differentially expressed in the two resistant lines (eight
downregulated and four upregulated). When compared with
the nine genes identified in our original siRNA screen, the ubiq-
uitin ligase RNF125 emerged as the primary candidate in both
analyses. RNF125 expression was significantly lower in resis-
tant cells than in parental cells, and RNF125 depletion in
parental cells conferred a growth advantage in the presenceCof BRAFi (Figures 1D, 1E, and S1C). In agreement with micro-
array data sets, RNF125 transcript and protein levels were
markedly decreased in the two resistant cultures (A375R and
Lu1205R) compared with parental cultures (Figures 1F and
S1C). RNF125 is implicated in T cell activation via regulation
of the T cell receptor and in the innate immune response to viral
infection via regulation of DDX58/RIG-I (Arimoto et al., 2007;
Giannini et al., 2008; Shoji-Kawata et al., 2007; Zhao et al.,
2005). Correspondingly, the expression levels of the known
RNF125 substrate DDX58/RIG-I were increased in BRAFi-resis-
tant cells (Figure 1F).
Altered RNF125 Expression Impacts Melanoma
Resistance to BRAFi
Next, we asked whether RNF125 expression is associated
with intrinsic BRAFi resistance. We conducted independent
analyses of melanoma cell lines (10 and 12 melanoma cell
lines in two respective experiments) and found an inverse corre-
lation between BRAFi resistance and RNF125 expression levels
(r = –0.75, p = 0.0051) (Figures 2A, 2B, and S2A; Table S1).
Notably, RNF125 knockdown in melanoma cultures increased
the BRAFi IC50 (p < 0.0001; Figures 2C and S2B–S2E). Interest-
ingly, RNF125 depletion in parental cells did not confer a degree
of resistance comparable to that seen in resistant cells, implying
that RNF125 may play a role in growth adaptation or fitness
phenotypes of BRAFi-resistant cells.
To confirm that lower RNF125 expression is associated
with BRAFi resistance of melanoma cells, we carried out
RNF125 gain-of-function experiments to monitor potential
changes in the resistance of these cultures. Notably, overex-
pression of wild-type (WT) RNF125 slowed the growth of
resistant, but not parental, cells, as seen in short-term 2D
and long-term 3D cultures (Figures 2D and 2E). Moreover,
this effect required E3 ligase activity (Figures 2D and 2E), as
overexpression of the RNF125 RING mutant had no effect.
Similarly, expression of WT protein, but not the RING mutant,
inhibited growth in UACC113 melanoma cells expressing low
levels of RNF125 (Figure 2F). These data establish the impor-
tance of RNF125 depletion in intrinsic BRAFi resistance and
adaptive resistance, both of which play key, albeit distinct,
roles in the propensity of melanoma to resist therapy (Kugel
and Aplin, 2014).
Identification of JAK1 as an RNF125 Substrate
To identify RNF125 substrates that mediate these effects, we
performed liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis in BRAFi-resistant melanoma cultures us-
ing the RING mutant form of RNF125, which is more stable.
Among 21 putative RNF125 substrates was JAK1, a key regu-
lator of immune cell activation and interferon responses (Table
S2), consistent with RNF125’s reported role in immune re-
sponses (Arimoto et al., 2007; Zhao et al., 2005). When we over-
expressed tagged forms of JAK1 and the RNF125 RING mutant
in HEK293T cells, we found that they interacted (Figure 3A). In
the presence of MG132, we detected interaction of endogenous
RNF125 and JAK1 using two different JAK1 antibodies (Fig-
ure 3B). Next, we assessed whether RNF125 regulated JAK1
stability. Following ectopic expression of RNF125 and JAK1,ell Reports 11, 1458–1473, June 9, 2015 ª2015 The Authors 1459
Figure 1. Identification of RNF125 in BRAFi-Resistant Melanoma Based on siRNA Screening and Gene Expression Analysis
(A) Experimental scheme of siRNA screening.
(B) Fold change in the growth of Lu1205 cells transfectedwith siRNAs and cultured in BRAFi (PLX4032, 1 mM) or DMSO (vehicle) for 72 hr. Red lines indicate >60%
viability and a >1.25-fold growth increase relative to siRNA controls in cells cultured in BRAFi.
(legend continued on next page)
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we found that RNF125 expression decreased JAK1 protein
steady-state levels in a manner dependent on RNF125 E3 ligase
activity (Figures 3C and 3D). Accordingly, RNF125 depletion by
two different small hairpin RNAs (shRNAs) increased the
steady-state levels of JAK1 protein, but not those of other JAK
family members (Figures S2B, S3E, and 3E). Notably, MG132
treatment increased JAK1 steady-state levels, masking the ef-
fect of RNF125 depletion and partially blocking deregulated
JAK1 expression by ectopically expressed RNF125 (Figure 3F).
Accordingly, the WT, but not the RING mutant form of
RNF125, decreased the JAK1 half-life by 50% (from 16.3 hr to
7.2 hr, based on linear regression analysis; Figure 3G). Collec-
tively, these findings identify JAK1 as a previously undisclosed
RNF125 substrate.
Regulation of JAK1 by RNF125 in BRAFi-Resistant Cells
Given the regulation of JAK1 stability by RNF125, we asked
whether JAK1 expression is altered in BRAFi-resistant cells.
We detected increased levels of JAK1 protein, but not mRNA,
in BRAFi-resistant cells (Figure 3H). To confirm that RNF125
deregulation increases JAK1 protein levels, we re-expressed
WT RNF125 and observed reduced JAK1 protein levels (Fig-
ure 3I). Cycloheximide chase experiments revealed an increased
JAK1 protein half-life in resistant cells (Figure 3J), which corre-
lated with decreased RNF125 expression (Figure 3H).
The SOX10/MITF Axis Is an Upstream Regulator of
RNF125 Expression
To identify genes that are potentially affected (positively or
negatively) by RNF125/JAK1 signaling, we used two different
data sets for resistant (Nazarian et al., 2010) or primary (Kraut-
hammer et al., 2012) melanoma cultures. We further analyzed
genes that were co-regulated with RNF125 expression (Pear-
son’s r > 0.7 or r < –0.7) using Ingenuity Pathway Analysis
(IPA). Among the top five co-regulated genes that we consid-
ered as putative upstream components were HNF4A, MITF,
and SOX10. Among these, SOX10 expression levels were posi-
tively correlated with RNF125. Thus, we set out to determine
whether SOX10 and its downstream target, MITF, may be up-
stream regulators of RNF125. SOX10 or MITF depletion signif-
icantly decreased RNF125 expression, whereas HNF4a deple-
tion did not (Figures 4A and S3A). By assessing independent
data sets (GEO: GSE37059, GSE50535) for genes regulated
by SOX10, we confirmed a positive correlation with RNF125
expression (Shakhova et al., 2012; Sun et al., 2014). These ob-
servations suggest that the SOX10/MITF axis is an upstream
regulator of RNF125, which carries corresponding SOX10-bind-
ing motifs and M box elements in its promoter regions (not
shown).(C) Genes selected in the first screening.
(D) Fold change in the growth of Lu1205 and A375 cells transfected with siRNAs t
growth increase; arrowhead indicates RNF125.
(E) Fold change in UPS-related gene expression in a data set of BRAFI-resistan
Selected genes were tested (see Figure S1C).
(F) Top: fold change in RNF125 expression in established cultures of resistant (Re
levels of RNF125 and its substrate DDX58/RIG-I.
Specific RNF125 bands are indicated with an arrow. Upper non-specific (n.s.) ba
CRNF125/JAK1 Affects EGFR Expression
A recent report links EGFR and SOX10 expression in BRAFi-
resistant melanomas (Sun et al., 2014). Notably, our gene clus-
tering analysis for genes that are co-expressed in melanoma
identified a link between RNF125 and EGFR expression (Figures
S3B and S3C). Thus, we assessed the potential effect of RNF125
expression on EGFR expression. RNF125 depletion increased
EGFR protein, but not mRNA, levels in A375, WM793, and
Lu1205 (Figures 4B and S4A) cells; however, further analysis
indicated that RNF125 does not interact with EGFR directly,
thus excluding EGFR as an RNF125 substrate (not shown).
Furthermore, RNF125 expression in additional melanoma lines
was also positively correlated with SOX10 expression (r = 0.75)
and inversely correlated with EGFR transcript (r = 0.65)
and protein expression (Figures 4C and S4B), suggesting
transcriptional and post-translational regulation of EGFR by
SOX10/RNF125.
As anticipated, JAK1 protein levels were higher in melanoma
cells that expressed low levels of RNF125 (Figure 4C).
Given the reported crosstalk between EGFR and JAK1, we
asked whether RNF125 regulates EGFR in a JAK1-dependent
manner (Cordero et al., 2012; Yamauchi et al., 1997). Notably,
JAK1 depletion in melanoma cells expressing higher levels
of EGFR significantly lowered EGFR protein levels without
altering EGFR transcription, supporting this hypothesis (Fig-
ure 4D). Conversely, JAK1 overexpression increased endoge-
nous EGFR protein levels (Figure 4E). Notably, SOX10 depletion
decreased RNF125 expression and increased EGFR transcript
levels, consistent with our own results (Figure S4C) and indepen-
dent studies (Sun et al., 2014). To assess a potential causative
role for SOX10 in the RNF125/JAK1/EGFR pathway, we as-
sessed the potential association of JAK1 levels with SOX10
expression. However, we found that JAK1 depletion did not alter
SOX10 expression, suggesting that JAK1 does not regulate
EGFR via SOX10 (Figure 4D). Transient SOX10 depletion in
A375 cells also led to reduced JAK1 mRNA and protein levels,
but increased those of EGFR (Sun et al., 2014) despite reduced
RNF125 expression (Figures S4C and S4D). This suggests that
there is an alternate route for control of JAK1 under certain con-
ditions that is independent of RNF125. Notably, unperturbed
melanoma cells, which exhibit reduced SOX10, also exhibited
reduced RNF125 expression and elevated JAK1 and EGFR
expression (Figure 4C), pointing to the primary role of RNF125
in controlling JAK1 expression concomitantly with the effect of
EGFR expression. Importantly, JAK1 knockdown in SOX10-
depleted melanoma cells completely abrogated SOX10-medi-
ated EGFR protein upregulation without altering EGFR transcript
levels. These observations suggest that in addition to the
SOX10/EGFR regulatory axis, the RNF125/JAK1 pathwayargeting genes selected in the first screening. The red line indicates a 1.25-fold
t melanoma (Nazarian et al., 2010). Red lines indicate a 1.25-fold difference.
s) lines relative to parental (Par) cells. Bottom: immunoblot showing the protein
nd is marked. Data are presented as mean ± SD. See also Figure S1.
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Figure 2. RNF125’s Function in BRAFi Resistance
(A) IC50 of the BRAFi (PLX4032) in melanoma cell lines (Table S1).
(B) Correlation of PLX4032 IC50 with RNF125 expression (based on qPCR; Table S1).
(C) BRAFi-induced growth inhibition of UACC91 cells expressing scrambled shRNA or two shRNAs targeting RNF125. Shown are the IC50 changes and cor-
responding protein expression following shRNA treatment. Effectiveness of shRNF125 measured by qPCR and by western blot, which depicts level of RNF125
and its reported substrate DDX58. Specific RNF125 band is pointed by arrow. The p values (paired, two-tailed Student’s t test) in the analyses using two shRNAs
were <0.0001.
(legend continued on next page)
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constitutes an independent regulatory module that controls
EGFR expression, as seen in melanoma harboring low SOX10
and high EGFR expression (Figures 4F and 4G).
To substantiate the link between JAK1 and EGFR expression,
we assessed pharmacological inhibitors of JAK, which are
known to affect different members of the JAK family. Notably, in-
hibition of JAK activity decreased EGFR expression (Figures 4H
and S4E). Interestingly, downregulation of EGFR following treat-
ment with JAK inhibitors (JAKi) occurred at transcriptional and
post-translational levels depending on the inhibitor used to
attenuate JAK activity (Figure 4H). Other mechanisms that could
account for the effect of JAK1 on EGFR expression may involve
the adaptor protein GRB2 and the ubiquitin ligase CBL, both of
which interact with JAK1 and EGFR andmodulate EGFR expres-
sion (Giorgetti-Peraldi et al., 1995; Meisner et al., 1995). The
reduced EGFR expression seen in JAK1-depleted cells was un-
changed by the presence of proteasome inhibitors, indicating
that this effect is independent of the UPS (Figure S4F).
Inhibition of JAK1 Resolves Melanoma Resistance to
BRAFi
We next asked whether the RNF125/JAK1/EGFR axis contrib-
utes to BRAFi resistance. First, we determined whether JAK1
depletion altered BRAFi resistance in an RNF125-dependent
manner. RNF125 depletion increased the BRAFi IC50 from 0.78
to 1.95 mM, and decreased it to 0.58 mM upon additional deple-
tion of JAK1 (Figure 5A). These observations suggest that the
BRAFi resistance seen in RNF125-depleted cells is primarily
due to perturbations in JAK1 expression/activity. Next, we
tested whether depletion of JAK1 and EGFR altered the resis-
tance of cells showing a high BRAFi IC50. Whereas EGFR deple-
tion partially attenuated BRAFi resistance (6.43–4.73 mM), JAK1
depletion alone or together with EGFR depletion had amore pro-
nounced effect (2.1 and 2.43 mM, respectively; Figure 5B).
Given the robust effect of RNF125 depletion on BRAFi-resis-
tant cell growth, we asked whether altered JAK1 or EGFR
expression phenocopied altered RNF125 expression. Similar to
the effects of RNF125 on BRAFi-resistant cells, depletion of
JAK1 or EGFR significantly inhibited the growth of BRAFi-resis-
tant cells in 2D culture (to 42% of controls following JAK1
knockdown and 28% following EGFR knockdown; Figure 5C).
Similarly, depletion of JAK1 or EGFR attenuated the 3D growth
of resistant melanoma cells in soft agar (Figure 5D). Analyses
of MAPK/ERK and PI3K/AKT pathways in parental and BRAFi-
resistant cells depleted of JAK1 or EGFR also revealed a mark-
edly reduced AKT activity in resistant, but not parental, cells
(Figure 5E), pointing to a MAPK/ERK-independent mechanism
underlying BRAFi resistance.
Unlike JAK1 depletion, EGFR depletion did not rescue drug
sensitivity in BRAFi-resistant cells. Thus, we asked whether(D) Fold difference in the growth of A375 cells transfected with empty vector (EV), w
with or without BRAFi (DMSO in parental and BRAFi [5 mM] in resistant cells). Th
difference was calculated to set the value in EV to one.
(E) Growth of A375R cells in soft agar. A375R cells expressing the indicated level
number was quantified using ImageJ.
(F) UACC1113 cell growth upon expression of the indicated plasmids for 72 hr. T
Data are presented as mean ± SD (A and C–F). See also Figure S2 and Table S1
CJAK1 signaling regulates other RTKs or their ligands that we
identified in our bioinformatics analysis (Figure S3) or have
been shown independently to be associated with BRAFi resis-
tance (Konieczkowski et al., 2014; Mu¨ller et al., 2014; Nazarian
et al., 2010; Sos et al., 2014). The transcript levels for four of
the five genes encoding RTKs or their ligands (GAS6, IL6, KIT,
and PDGFR, but not AXL) decreased following JAK1 knockdown
(Figures 5F and S4G). Notably, levels of AXL protein, an RTK
linked to BRAFi resistance (Konieczkowski et al., 2014; Mu¨ller
et al., 2014), were reduced following JAK1 depletion by two of
the three shRNAs used, or treatment with a JAK1 inhibitor (Fig-
ures 5F and 5H). The latter is consistent with the inverse correla-
tion we observed for GAS6/AXL and RNF125 expression, and is
similar to that seen for EGFR and RNF125 (Figure 5G). In all, our
data suggest that JAK1 regulates the expression of several fac-
tors implicated in BRAFi resistance, including EGFR, GAS6/AXL,
IL6, KIT, and PDGFR.
To confirm the genetic data, we assessed whether treatment
with pharmacological inhibitors of EGFR (gefitinib) or JAK1 (pyr-
idone 6 or AZD1480) would alter the growth of BRAFi-resistant
A375R or Lu1205R cells. Gefitinib, either alone or in combination
with a BRAFi, did not block the growth of either line in soft agar;
however, a combination of a BRAFi and the JAKi pyridone 6 or a
triple combination of BRAFi plus pyridone 6 and gefitinib signif-
icantly and dose-dependently attenuated the growth of BRAFi-
resistant melanomas (Figure 6A). Similarly, combined treatment
with a BRAFi and the JAKi AZD1480 blocked the growth of
Lu1205R cells (Figure S5A), suggesting that increased expres-
sion of JAK1 and EGFR is essential to maintain BRAFi-resistant
cell growth.
To validate these findings, we employed a xenograft model
in mice using BRAFi-resistant A375 tumors that had relapsed
in vivo. These mouse-derived A375R (M) cells exhibited a 100-
fold higher BRAFi IC50 than their parental line and expressed
low levels of RNF125 and elevated levels of JAK1 and EGFR
(Figures 6B and 6C). In two independent assessments, we moni-
tored the effect of BRAFi alone (PLX4720 fed in chow) or in com-
bination with the JAKi AZD1480 together with the EGFR inhibitor
(EGFRi) gefitinib. Significantly, the growth of the BRAFi-resistant
A375 tumors was attenuated (60%) when mice were adminis-
tered the combination treatment compared with BRAFi alone
(n = 9 per group, p = 0.01147; Figure 6D). As observed in cultured
cells, expression of both EGFR and AXL also decreased in the
BRAFi+JAKi+EGFRi-treated group (Figure 6E).
RNF125 Expression Inversely Correlates with BRAFi
Resistance in Melanoma Specimens
To confirm the cell culture and xenograft analyses, we assessed
tumor specimens obtained from patient-derived xenografts
(PDXs). PDXs generated from BRAFi-resistant tumors showedild-type RNF125 (WT), or the RINGmutant (RM) and cultured for 72 hr in media
e growth was assessed using ATPlite (see Experimental Procedures). The fold
s of RNF125 were plated and cultured in the presence of BRAFi (5 mM). Colony
he fold difference in growth was assessed as described above.
.
ell Reports 11, 1458–1473, June 9, 2015 ª2015 The Authors 1463
A B C
D E F
G H
I J
Figure 3. JAK1 Is a Novel RNF125 Substrate
(A) The RNF125-JAK1 interaction was analyzed in HEK293T cells ectopically expressing FLAG-tagged RNF125 and V5-tagged JAK1. IgLC, IgG light chain.
Arrows point to the position of RNF125 protein; n.s. indicates non-specific band.
(B) Interaction of endogenous RNF125 with JAK1 analyzed in A375 cells pre-treated with MG132 (5 mM) for 10 hr. Two independent experiments were conducted
using two different JAK1 antibodies. Asterisks indicate RNF125.
(C) JAK1 deregulation by RNF125 in HEK293T cells ectopically expressing the indicated amounts of plasmids. GFP served as a transfection control.
(D) JAK1 expression analyzed in Lu1205 cells transfected with the indicated RNF125 plasmids (empty vector [EV], wild-type [WT], or RING mutant [RM]).
(E) JAK1 expression was analyzed in A375 cells expressing scrambled shRNA (Scr) or two shRNAs (#1 and #2) targeting RNF125.
(F) JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 mM, 10 hr), and in Lu1205 cells
expressing WT RNF125 and treated with MG132.
(legend continued on next page)
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reduced RNF125 expression in nine of 17 tumors (a marked
reduction in three and a more modest but significant reduction
in six; Figure S5B). Interestingly, three of the 17 tumors exhibited
a marked reduction in RNF125 expression that was associated
with BRAFi resistance (Figure S5B), indicating that the
RNF125/JAK1 axis would be relevant in a fraction of BRAFi-
resistant tumors. To further assess changes associated with
JAK1 expression, we monitored STAT3 activation, a reliable sur-
rogate for JAK1 activity, which is also implicated in BRAFi resis-
tance (Figure S5C; Girotti et al., 2013; Liu et al., 2013; Sos et al.,
2014). Increased STAT3 phosphorylation (pSTAT) was seen in
specimens exhibiting reduced RNF125 expression but not in
tumors with unaltered RNF125 expression (Figures 7A and
S5D). Moreover, analyses of three melanoma transcriptome
data sets (GEO: GSE24862, GSE31534, GSE36139) identified
a five-gene signature of STAT3-regulated genes, which coin-
cided with reduced RNF125 and enhanced BRAFi resistance
(Figures S6A–S6F; Barretina et al., 2012; Nazarian et al., 2010;
Wang et al., 2012). Notably, that signature was highly correlated
with pSTAT3 staining (Figures 7A and 7B). Likewise, in sections
from BRAFi-resistant, PDX-derived specimens, pSTAT3 staining
was inversely correlated with RNF125 staining (Figure 7C).
Notably, expression of the STAT3-signature genes was signifi-
cantly higher in tissue sections derived from patients with pro-
gressed forms of the disease (Figure 7D).
We next validated these findings using tumor specimens
derived frommelanoma patients. RNF125 expression in samples
from patients treated with BRAFi was significantly higher in the
initial phase of treatment (ON, response phase) but decreased
during the progression phase (PRO, resistant phase) (Figure 7E;
Table S3). Notably, Kaplan-Meier analysis suggested that pa-
tients whose tumors showed higher RNF125 levels at the
response phase (ON treatment) had a longer survival time than
those whose tumors exhibited lower levels (n = 17, p = 0.02; Fig-
ure 7F). A detailed comparison of RNF125 expression in six
matched samples revealed that RNF125 expressionwas reduced
in about half of the cases, indicating that our findings are relevant
to a significant subset of resistant tumors (Figure S5E). As seen in
resistant cells, RNF125 protein expression during the progres-
sion/resistance phases decreased relative to levels seen in the
pre-treatment phase in patient tissues (Figures 7C and 7G).
Further analysis of the correlation between RNF125 expression
and time to progression, or best response evaluation criteria in
solid tumors (RECIST) score, showed that 16 of 22 patients ex-
hibited a significant correlation (r = 0.70, p = 0.003; Figure 7H).
Of interest, the level of RNF125 expression during treatment
(ON phase) could be associated with survival, even in the outlier
cases (Figures 7F and S5F). Correspondingly, analysis of the
RECIST scores also suggested that patients expressing higher
RNF125 levels showed a better response to BRAFi (Figure 7I).(G) A375 cells expressing scrambled shRNA or shRNF125 (#2) were subjected
quantified using LICOR.
(H) Increased expression of JAK1 protein in established UACC91-resistant (UACC
band is pointed by arrow. Upper non-specific (n.s.) bands are marked. Data are
(I) JAK1 expression in A375R and Lu1205R cells was analyzed following transfec
(J) Cycloheximide chase analysis was performed in Lu1205 parental and resista
See also Table S2 and Figure S3.
CDISCUSSION
The need to identify mechanisms underlying melanoma cell
resistance to existing therapies has fueled intensive investiga-
tion. Most studies have focused on pathways that alter MAPK
signaling, either through mutation or differential splicing of
BRAF or through upregulation of related receptors, including
PDGFR and EGFR. Here, we identify a previously undisclosed
mechanism that increases EGFR expression through deregula-
tion of the ubiquitin ligase RNF125. We find that RNF125 dereg-
ulation alters EGFR expression indirectly by controlling JAK1, a
newly described RNF125 substrate. In addition to its effect on
EGFR, JAK1 expression was also found to regulate other genes,
including GAS6/AXL, IL6, KIT, and PDGFR, all of which are impli-
cated in BRAFi resistance (Konieczkowski et al., 2014; Mu¨ller
et al., 2014; Nazarian et al., 2010; Sos et al., 2014). As previously
demonstrated, targeting multiple pathways is likely to be more
efficacious for eradicating tumor cells than targeting EGFR alone
(Mu¨ller et al., 2014). Thus, the effect of JAKis on the regulation of
multiple RTKs linked to BRAFi resistance may offer an efficient
therapeutic modality.
We observed a link between RNF125 activity and melanoma
resistance in cultures of melanoma cells obtained from resistant
tumors, in melanoma cells that developed BRAFi resistance in
culture, in xenografts and PDX from BRAFi-resistant tumors,
and in tumor samples obtained at the time of resistance onset.
Each assessment supports a causal role for RNF125 and
JAK in BRAFi-resistant melanoma. Significantly, the growth of
BRAFi-resistant xenografts was effectively attenuated using a
combination of BRAFi, JAKi, and EGFRi. Our bioinformatics
analysis indicated an effect of RNF125/JAK1 on several RTKs
implicated in BRAFi resistance and confirmed them as part of
the greater JAK1 network (Figures S3B–S3D). Given thatmultiple
mechanisms underlie BRAFi resistance, including NRAS and
MEK mutations and alternate BRAF splicing, the mechanism
identified here should be relevant to the subset of BRAFi-resis-
tant melanoma tumors. Our initial assessment of three indepen-
dent sets of patient tumors resistant to BRAFi suggests that the
RNF125/JAK1 regulatory axis described here is relevant to a
sizeable fraction of these tumors, which is a prediction that
should be confirmed using larger cohorts.
Interestingly, RNF125 levels are also notably lower in other tu-
mor types (such as colorectal cancer) that exhibit a poor
response to BRAFi (GEO: GSE36139) (Barretina et al., 2012; Pra-
hallad et al., 2012). Thus, it will be interesting to assess RNF125’s
function in conferring resistance to BRAFi or other MAPK inhib-
itors in these cancer types.
Our findings also suggest that SOX10 regulates EGFR both
transcriptionally (directly) and post-translationally (via RNF125
destabilization of JAK1), indicating that SOX10 constitutes ato cycloheximide chase (50 mg/ml for indicated times). Band intensity was
91R) cells in the absence of changes in JAK1 transcript levels. Specific RNF125
presented as mean ± SD.
tion with WT RNF125 plasmid.
nt cells. Band intensity was quantified as above.
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Figure 4. EGFR Post-transcriptional Regulation by RNF125
(A) RNF125 expression in A375 cells expressing indicated shRNAs.
(B) Left: EGFR expression in A375 andWM793 cells expressing control or shRNF125. Upper non-specific (n.s.) bands are marked. Right: corresponding changes
in EGFR mRNA levels. Specific RNF125 bands are indicated with an arrow.
(C) Analysis of EGFR and JAK1 protein (upper) and transcript (lower) levels in UACC lines. Specific RNF125 bands are indicated with an arrow. Upper non-specific
(n.s.) bands are marked.
(D) Left: UACC1113 cells expressing JAK1 shRNAs were analyzed for EGFR, JAK1, and SOX10 expression. Right: corresponding transcript levels were analyzed.
(E) EGFR expression in HeLa cells transfected with indicated plasmids.
(F) A375 cells were transduced with the indicated shRNAs and assessed for expression of EGFR, JAK1, and SOX10.
(legend continued on next page)
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common regulatory hub underlying the control of resistance
phenotypes. Consistent with this observation, SOX10 regulation
of MITF expression and increased signaling via NF-kB and the
receptor tyrosine kinase AXL have been linked to primary resis-
tance to BRAFi in a subset of melanomas (Kim and Ronai, 2015;
Konieczkowski et al., 2014; Mu¨ller et al., 2014). In all cases,
reduced levels of SOX10,MITF, or RNF125were shown to confer
resistance. Importantly, our observations suggest that RNF125
downregulation maintains resistance phenotypes, consistent
with our current understanding of adaptive resistance and its
importance for cell growth and survival (Kugel and Aplin, 2014).
The lower RNF125 expression seen in cells with intrinsic or adap-
tive resistance confers fitness benefits by upregulating JAK and
EGFR signaling. A critical role for the RNF125 regulatory axis is
also reflected in our network analysis, which demonstrates that
RNF125 control of JAK1 is linked to the expression of many
genes that are deregulated in association with BRAFi resistance
(Figure S3D) confirming, the importance of this axis in melanoma
resistance. Taken together, our data suggest that combined
inhibition of JAK and EGFR offers a significant advantage for
attenuating the growth of BRAFi-resistant melanoma and could
constitute a therapeutic modality to overcome BRAFi-resistant
tumors.
EXPERIMENTAL PROCEDURES
Cell Lines and Establishment of Resistant Cells
Melanoma (A375, Lu1205, WM9, WM35, WM793, SK-Mel-28, and SK-Mel-
29), HeLa, and HEK293T cells were cultured in DMEM (Life Technology)
supplemented with 10% fetal bovine serum and penicillin/streptomycin. Mel-
anoma UACC cell lines were maintained in RPMI1640 medium (Life Technol-
ogy) supplemented with 10% fetal bovine serum and penicillin/streptomycin.
Resistant cells were established in culture by increasing PLX4032 levels at
each passage and maintaining them in media containing PLX4032 (A375
[5 mM], Lu1205 [5 mM], and UACC91 [1 mM]). A375R (M) cells (in vivo-generated
BRAFi-resistant cells) were isolated from relapsed tumors and expanded in
media without BRAFi for xenograft analysis and characterization.
Reagents and Antibodies
The BRAFi PLX4032, the EGFRi gefitinib/ZD1839, and the JAKi AZD1480 were
purchased from Selleckchem. The JAKi pyridone 6 was purchased from Milli-
pore. The following antibodies were used: FLAG-tag from Sigma-Aldrich;
V5-tag from Life Technology or Bethyl Laboratories; Stat3, b-actin, GFP, and
control IgG from Santa Cruz; TYK2 from BD Biosciences; JAK2, JAK3,
EGFR, AXL, pSTAT3, and DDX58/RIG-I from Cell Signaling; GAS6 from R&D
Systems; RNF125 from Life Technology, Bethyl Laboratories, AbCam, or
Sigma-Aldrich; and JAK1 from Santa Cruz, BD Biosciences, Cell Signaling,
or EMD Millipore.
Screen for BRAFi-Resistance-Associated Genes
Screening was performed using siRNAs targeting 1,173 UPS-related genes
(consisting of ubiquitin ligases, ubiquitin-like proteins, and deubiquitination en-
zymes). Each gene was represented by three different sets of siRNAs. siRNA
transfection was performed according to the reverse transfection method in
384-well format using RNAimax (Life Technology). Using 48 nonspecific
siRNAs and three killer siRNAs (targeting genes essential for viability), we
tested the transfection efficiency and calculated the z-factor of viability using(G) Corresponding changes in transcript levels (EGFR, JAK1, and SOX10).
(H) Top: A375R (M) cells, which are BRAFi-resistant cells generated in vivo, were
protein expression. Bottom: corresponding changes in transcript levels.
*p < 0.01 and **p < 0.05 unless otherwise specified. Data are presented as mean
Ctwo different BRAFi concentrations (1 and 5 mM). At both concentrations, the
latter value ranged from 0.8 to 0.9 in Lu1205 parental and resistant cells. For
reverse transfection of siRNAs, 1 ml of each siRNA (0.5 mM), including control
siRNAs (nonspecific and killer), was spotted per well. After a 30-min reaction
in the presence of RNAimax (0.1 ml in 10 ml Opti-MEM; Life Technology),
parental or BRAFi-resistant cells (3,500 cells/40 ml of medium) were added.
Twenty-four hours later, 10 ml of BRAFi (final concentration: 1 mM for parental
cells and 5 mM for resistant cells) was added. Cell growth and viability were
determined 72 hr later using ATPlite (Perkin Elmer) according to the manufac-
turer’s recommendation. Fold differences in cell growth were calculated by
dividing values from vehicle (DMSO)-treated wells by values from BRAFi-
treated wells. The fold differences from each siRNA set were further analyzed.
Secondary screening was repeated using A375 and Lu1205 lines under the
same conditions.
Cell Viability Assay in 2D Culture
Cell growth was assayed using ATPlite (Perkin Elmer). Briefly, melanoma cells
(5,000 cells/well) were cultured in 96-well plates with a transparent bottom.
Twenty-four hours after seeding, inhibitors were added for 72 or 120 hr. Cell
growth or viability was measured using ATPlite (Perkin Elmer) and quantified
by monitoring luminescence intensity.
Soft Agar Assay
Soft agar culture was performed using standard methods. Briefly, 50,000 mel-
anoma cells in top agar (0.35% in 13 DMEM) were plated over a second layer
of agar (0.7% in 13 DMEM). After 24 hr, medium containing various com-
pounds was added over the top agar and changed every 5 days. Colonies
were visualized by crystal violet staining (0.005% crystal violet in 4% parafor-
maldehyde/PBS). Images were acquired with a microscope (340) or scanned
(HP ScanJet G4010). Colony number and size were analyzed using ImageJ
software (NIH).
Patient Samples
Patients with metastatic melanoma containing a BRAFV600E mutation
(confirmed by genotyping) were enrolled in clinical trials of a BRAFi or com-
bined BRAF+MEK inhibitors (Table S3). Consent was obtained for tissue
acquisition in accordance with a protocol approved by the Institutional Review
Board and the conventions of the Helsinki Declaration on Human Rights.
Tumor biopsies were collected pre-treatment (on day 0), after 10–14 days of
treatment, and/or at the time of progression, if applicable. Formalin-fixed tis-
sue was analyzed with H&E staining to confirm the presence of a viable tumor.
Additional tissue was snap-frozen and stored in liquid nitrogen or was pro-
cessed immediately for RNA purification.
PDXs were established by grafting melanoma tumor biopsies from pa-
tients subcutaneously into immunodeficient NSG mice with Matrigel (BD
Biosciences). The animals were monitored weekly for tumor growth and
live tissue was banked or serially transplanted when the tumors reached
maximal volume. In PDXs established from BRAFi therapy-relapsed pa-
tients, tumors were grown under a PLX4720 200 ppm diet. All studies
were conducted in accordance with the Wistar Institutional Animal Care
and Use Committee.
Immunohistochemistry
Tumor biopsies were stained with primary antibodies for RNF125
(HPA041514; Sigma-Aldrich) followed by a secondary antibody conjugated
to horseradish peroxidase and treated with 3,30-diaminobenzidine (DAB) chro-
mogen. Stained slides were interpreted by a dedicated dermatopathologist.
Only positive signals with clear melanoma morphology were evaluated. For
immunofluorescence, the primary antibodies were RNF125 and pSTAT3
(both diluted 1:1,000; Cell Signaling), and signals were amplified using the
TSA-Biotin Plus System (Perkin Elmer) according to the manufacturer’streated with the indicated concentrations of a JAKi for 24 hr and assessed for
± SD (A–D, G, and H).
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Figure 5. JAK1 and EGFR Signaling Maintains the Growth of Resistant Cells
(A) UACC91 cells were subjected to double knockdown with the indicated combinations of shRNAs and analyzed for cell growth. Bottom: RNF125/JAK1
knockdown efficiency was evaluated by qPCR.
(B) Analysis of BRAFi-mediated growth inhibition of UACC1113 cells expressing the indicated shRNAs. Bottom: knockdown efficiency was evaluated by qPCR.
(C) Analysis of growth of A375R cells transiently infected with lentivirus harboring the indicated shRNAs after 72 hr of culture.
(legend continued on next page)
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Figure 6. Inhibition of JAK1 and EGFR
Blocks the Growth of Resistant Cells
(A) A375R cells were grown for 2 weeks in soft agar
in the presence of BRAFi (PLX4032), EGFRi (gefi-
tinib), and JAKi (pyridone 6).
(B) BRAFi IC50 in parental and in vivo-generated
resistant cells. IC50 = 0.003 and 3.18 mM in
parental and resistant cells, respectively.
(C) Levels of the indicated transcripts and proteins
in parental and resistant cells. *p < 0.05.
(D) Tumor growth changes in athymic nude mice
injected with A375R (M) were monitored in two
groups (BRAFi only and BRAFi+JAKi+EGFRi).
Tumor volume is shown as the fold difference
relative to tumor volume at day 0. Inset: images of
three representative tumors at the end of the
experiment. Because some tumors developed
slower, their treatment begun at later time points,
and their collectionband respective pictures were
delayed (indicated by dotted line). See also the
Experimental Procedures.
(E) Levels of the indicated proteins in the tumors
shown in (D).
Data are presented as mean ± SD (A–C). See also
Figure S5.instructions. The same slides were counterstained with S-100 (1:400; Dako).
Immunofluorescence-stained slides were visualized using a fluorescence mi-
croscope with a Slidebook or Aperio slide scanner.
DNA Constructs, Transfection, and Transduction
FLAG-tagged RNF125 vectors were constructed by subcloning PCR prod-
ucts from MEF cDNA into pcDNA3.0-C-FLAG. The FLAG-tagged fragment
was then subcloned into the pBabe retroviral vector. RNA125 RING
domain mutations (C37 and 40A) were introduced by site-directed muta-(D) Growth of the A375R cells in (C) analyzed in soft agar.
(E) Cell lysates from parental (A375) and resistant (A375R) cells expressing the indicated shRNAs were analyz
band intensities were normalized to b-actin and quantified. Phospho-AKT and phospho-ERK were normaliz
(F) Expression of the indicated transcripts (upper) and proteins (lower) in UACC1113 cells depleted of JAK1
(G) Expression of GAS6 and AXL transcripts and protein in lysates of UACC lines expressing low (612, 647,
(H) Changes in AXL expression following treatment of mouse-derived A375R (M) cells and UACC1113, which r
with various concentrations of JAKi (AZD1480) for 24 hr.
*p < 0.01 and **p < 0.05 unless otherwise specified. Data are presented as mean ± SD (A–D, F, and G). See
Cell Reports 11, 1458–14genesis (Agilent Technology). A JAK1 expres-
sion vector was constructed in pLX304-V5
Gateway vectors from pDONR223-JAK1 (Addg-
ene #23932).
Cells were transiently transfected using Jet-
Prime (Polyplus Transfection). For viral transduc-
tion, viral particles were harvested after calcium
phosphate transfection of HEK293T cells with
plasmid vectors and appropriate packaging
plasmids. Target cells were infected with virus
particles by spinoculation (1,600 3 g for
30 min at room temperature) in the presence of
4 mg/ml polybrene (Sigma-Aldrich). Stable
clones were established by culture in media
containing puromycin (1 mg/ml; InvivoGen) or
blasticidin (5 mg/ml; Sigma-Aldrich).
Cycloheximide Chase Assay
Cycloheximide chase was performed as
described previously (Kim et al., 2014). Briefly,cycloheximide (50 mg/ml) was added to cells at the indicated times. Cell lysates
were prepared as described previously (Kim et al., 2014) and analyzed with the
indicated antibodies.
Immunoprecipitation and Immunoblotting
To detect protein interactions, cell lysates were prepared using 1% Triton-
lysis buffer (50 mM Tris-HCl [pH 7.4] and 150 mMNaCl) spiked with protease
and phosphatase inhibitors (Thermo Scientific). Lysates pre-cleared with
beads (Protein A/G agarose bead; Santa Cruz) were incubated with theed using the indicated antibodies. EGFR and JAK1
ed to the respective total proteins and quantified.
.
and 1,113) and high (91 and 502) RNF125 levels.
epresent melanomawith intrinsic resistance (lower)
also Figure S4.
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Figure 7. Correlation of RNF125 Expression and BRAFi Resistance in Melanoma Patients
(A) RNF125 and pSTAT3 expression levels were assessed in tissue sections from PDX tumors treated with or without BRAFi. The upper two sections (3936-1 and
3936-2) and the lower section (4070-2) represent responders (in which RNF125 levels are reduced by BRAFi) and non-responders (no changes in RNF125
following BRAFi treatment), respectively (Figure S5B). Scale bar indicates 100 mm.
(B) Analysis of five STAT3 signature genes in three responders and two non-responders (Figures S5B and S6).
(C) RNF125 and pSTAT3 expressionwas assessed in tissue sections frompatients before treatment (PRE) and after disease progression (PRO). Size bar indicates
500 (43) and 100 (203) mm, respectively.
(D) Analysis of five STAT3-signature genes in 11 PRE (black) and 14 PRO (red) melanoma patients. Following normalization to 18S RNA, the fold difference for the
expression of each gene was calculated relative to the average value of the PRE samples (set to one). The statistical significance (p value) was determined by the
Mann-Whitney U test. The number of samples analyzed for each gene is indicated. Bars indicate mean ± SEM
(legend continued on next page)
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appropriate antibodies overnight at 4C, and then protein A/G agarose beads
were added and the incubation continued for an additional 2 hr at 4C. Beads
were washed with lysis buffer, boiled in Laemmli buffer, and subjected to
SDS-PAGE. To detect endogenous JAK1-RNF125 interactions, A375 cells
were pretreated with MG132 (10 mM; Selleckchem) for 5 hr before lysis and
immunoprecipitation with an anti-JAK1 antibody (BD Bioscience and EMD
Millipore). For immunoblotting, cell or tumor lysates were prepared using
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% [v/v] NP-40, 0.1% [w/v] sodium de-
oxycholate, 0.1% [w/v] SDS, 150 mM NaCl, 1 mM EDTA, a protease inhibitor
cocktail [Roche], and PhoStop [Roche]). Imaging of immunoblots was per-
formed with the aid of LICOR system using respective fluorescence anti-
bodies. A horizontal line indicates cases where the membrane was split to
enable reactions with multiple antibodies. In cases of overexpression,
RNF125 is seen as a single band. When endogenous protein was followed,
a doublet was identified. The identity of the specific RNF125 band was
confirmed by qPCR where a corresponding change were also seen at the
transcript levels. Specific RNF125 band is pointed by arrow. Non-specific
(n.s.) band is noted.
qPCR
Total RNA was obtained with GenElute (Sigma-Aldrich) and subjected to
reverse transcription using high-capacity cDNA synthesis kits (Applied Bio-
systems). For qPCR, cDNAs were analyzed with CFX Connect (BioRad) us-
ing Faststart Universal Cyber Green Master Mix (Roche) according to the
manufacturer’s directions. Total RNA from patient biopsies was obtained
using an RNeasy kit on a QiaCube apparatus (QIAGEN) and served as
the template (250 ng) to generate cDNA (Superscript VILO cDNA Synthesis
Kit; Invitrogen). Real-time qPCR was carried out on a LightCycler (Roche)
using Essential Green Master Mix (Roche). Transcript level differences
were analyzed according to the DDct method. Primer sequences are listed
in Table S4. Imaging of immunoblots was performed with the aid of LICOR
system using respective fluorescence antibodies. A horizontal line indi-
cates cases where the membrane was split to enable reactions with multi-
ple antibodies. In cases of overexpression, RNF125 is seen as a single
band. When endogenous protein was followed, a doublet was identified.
The identity of the specific RNF125 band was confirmed by qPCR where
corresponding change were also seen at the transcript levels. Specific
RNF125 bands are indicated with an arrow. Non-specific (n.s.) bands are
noted.
Mass Spectrometry
Melanoma A375 cells were transfected with control plasmid (pcDNA3.0 with a
FLAG-tagged C terminus) or plasmid encoding FLAG-tagged RNF125 (WT or
mutant RNF125RM form). Cells were lysed in 1% Triton-lysis buffer (50 mM
Tris-HCl [pH 7.4], 150mMNaCl, 1mMEDTA, 1% [v/v] Triton X-100, a protease
inhibitor cocktail [Roche], and PhoStop [Roche]) and pre-cleared with protein
A/G agarose beads (Santa Cruz). Immunoprecipitation was performed using
FLAG-M2-agarose beads (Sigma-Aldrich). After washing with lysis buffer,
bound proteins were eluted with FLAG-peptide (Sigma-Aldrich) according to
the manufacturer’s directions.
Samples for LC-MS/MS analysis were prepared according to standard pro-
cedures (Kim et al., 2014). In brief, protein samples were reduced, alkylated,
trypsin digested, and then desalted. Desalted samples were resuspended in
125 ml 0.1% TFA/0.2% acetonitrile in glass sample vials and then analyzed us-
ing a Michrom MDLC Paradigm MS4 HPLC system, HTC-PAL autosampler,
and LTQ OrbitrapXL mass spectrometer.(E) The expression of RNF125 transcript was analyzed in melanoma tissue co
development of progressive disease (PRO). ‘‘n’’ indicates the number of patients
(F) Kaplan-Meier analysis of melanoma patients exhibiting a low or high increase
(G) RNF125 protein expression in melanoma tissues collected from patients befo
(H) RNF125 expression (before treatment) normalized to GAPDHwas analyzed in
expression versus time to progression in 22 patients. A correlation coefficient was
(I) RNF125 expression was analyzed in terms of the best RECIST score. As in Figu
(filled circles) of 22 (outliers, blank circles) patients.
See also Figures S5 and S6 and Table S3.
CIn Vivo Xenograft
In vivo-generated BRAFi-resistant cells were injected (1.0 3 106, s.c.) into
the lower left flank of 6-week-old female athymic nude mice. Both the
BRAFi-only and BRAFi+JAKi+EGFRi groups were first fed BRAFi chow
(PLX4720, 417 ppm in chow; Research Diets) on the day of injection.
Once the tumors reached 50–100 mm3, the experimental group also
received JAKi (AZD1480, 50 mg/kg, oral gavage, once daily) and EGFRi
(gefitinib, 100 mg/kg, oral gavage, once daily), and the BRAFi-only control
group received vehicle only. Tumor size was monitored every 3–4 days until
the mice were euthanized. Tumors were collected from euthanized mice
and processed for further analyses. Because tumor growth rate varied
among the individual tumors, indicated treatment was initiated at
different time points (based on tumor size rather than time from injection).
Accordingly, tumor collection took place at two time points, respective of
treatment initialization. The Institutional Animal Care and Use Committee
(IACUC) of Sanford-Burnham Medical Research Institute approved our
study protocols.
Gene Silencing
pLKO.1 vectors targeting RNF125, JAK1, EGFR, HNF4a, SOX10, and MITF
were purchased from Thermo Scientific. After transduction of shRNA lenti-
virus, silencing efficiency was validated from cell lysates of stable clones using
the appropriate antibodies or by qPCR analysis of mRNA using the primers
shown in Table S4.
Statistical Analysis
Unless specified, data are presented as means ± SD and the significance of
differences was analyzed using a two-tailed, unpaired t test. Differences
with p values < 0.05 were considered significant. For analyses of a linear
correlation between two groups, Pearson’s correlation was calculated us-
ing Excel software unless otherwise specified. IC50 values were calculated
using Prism 6.0 software with non-linear regression to fit data to the
log values of inhibitor concentration versus the response values (fold
changes in luciferase activity). The R statistical package was used to
generate box plots. The p values from Pearson correlation coefficient
analysis were calculated with the following equation using Excel software:
p = 1-F.dist(((n-2)*r2)/(1-r2), 1, n-2, TRUE (n, number of data pairs; r, Pear-
son’s coefficient).
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